Clinical Report: Experts Prioritize 3 Drugs for Alzheimer's
Overview
A Delphi consensus of 23 experts has identified three drugs—herpes zoster vaccine (Zostavax), sildenafil, and riluzole—as high-priority candidates for Alzheimer disease clinical trials. The herpes zoster vaccine was ranked highest for acceptability and perceived benefit-risk balance.
Background
Alzheimer's disease (AD) is a leading cause of dementia and poses significant challenges for patients and healthcare systems. Identifying effective treatments is critical, especially as the prevalence of dementia is expected to rise dramatically in the coming decades. The repurposing of existing drugs may offer new therapeutic avenues for managing AD.
Data Highlights
{'Herpes Zoster Vaccine (Zostavax)': {'Key Findings': '20% relative reduction in dementia incidence'}}Key Findings
{'1': 'The herpes zoster vaccine showed a 20% relative reduction in new dementia diagnoses in a UK study.'}Clinical Implications
Healthcare professionals should consider the potential of repurposing existing drugs like the herpes zoster vaccine for Alzheimer's disease. Ongoing clinical trials are necessary to establish the efficacy and safety of these agents in AD populations.
Conclusion
The identification of these three drugs as priority candidates highlights the importance of innovative approaches in Alzheimer's treatment. Further research is essential to validate their effectiveness in clinical settings.
Related Resources & Content
- Drugs - Real World Outcomes, Evaluation of Anticholinergic and Sedative Medication Use Prior to and Following the Start of Anti-Dementia Treatments, 2015
- Archives of Toxicology, Addressing Oxidative Stress and Associated Conditions in Alzheimer’s Disease, 2019
- Drug Safety, Cognitive Dysfunction Associated with Pharmacological Agents, 2024
- Drug Safety, Prescribing Patterns of Antipsychotic Medications in Dementia Patients, 2017
- Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation, PMC, 2025
- RESEARCH ARTICLE, 2024
- Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease, Brain, 2021
- Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation - PMC
- RESEARCH ARTICLE
- Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease | Brain | Oxford Academic
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
